je.st
news
Mercks Durham Site Receives U.S. FDA Licensure for Varicella Bulk
2013-09-04 21:50:12| Merck.com - Corporate News
Dateline City: DURHAM, N.C. Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the companys site in Durham, N.C., for use in Mercks vaccines to protect against chickenpox and shingles. The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Mercks overall global supply capabilities. In 2010, the site was approved to produce finished chickenpox vaccines. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: site
bulk
receives
durham
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||